Across TCGA pan-cancer cohorts, CLDN4 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CLDN4’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CLDN4 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CLDN4 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where CLDN4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLDN4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	−0.315	.005	5	view →
LUAD	All	II,III,IV	−0.299	.012	3	view →
LSCC	All	III,IV	+0.489	.017	1	view →
COAD	All	III,IV	+0.410	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CLDN4 RNA expression & survival · all CLDN4 data types